Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin (2018 - 2025)

Historic Gross Margin for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to 84.03%.

  • Akebia Therapeutics' Gross Margin rose 218700.0% to 84.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.99%, marking a year-over-year decrease of 4379800.0%. This contributed to the annual value of 60.56% for FY2024, which is 7020500.0% up from last year.
  • Akebia Therapeutics' Gross Margin amounted to 84.03% in Q3 2025, which was up 218700.0% from 84.12% recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Gross Margin high stood at 114.53% for Q4 2023, and its period low was 0.79% during Q2 2021.
  • Moreover, its 5-year median value for Gross Margin was 62.16% (2024), whereas its average is 61.35%.
  • Per our database at Business Quant, Akebia Therapeutics' Gross Margin surged by 1696000bps in 2021 and then plummeted by -583300bps in 2024.
  • Akebia Therapeutics' Gross Margin (Quarter) stood at 17.42% in 2021, then surged by 509bps to 106.15% in 2022, then grew by 8bps to 114.53% in 2023, then plummeted by -51bps to 56.2% in 2024, then skyrocketed by 50bps to 84.03% in 2025.
  • Its Gross Margin was 84.03% in Q3 2025, compared to 84.12% in Q2 2025 and 86.7% in Q1 2025.